Doctiplus - We are allways here!

Mn-Sn: 8am to 9pm

Diabetes (Type 2) — Weekly Report — November 9, 2026

Home/Health Insights/Diabetes (Type 2) — November 9 – November 16, 2026
Vol. 7 · No. 47
DoctiPlus Care · Weekly Brief on Diabetes (Type 2)
Updated Monday · November 16, 2026
Diabetes (Type 2) · November 9 – November 16, 2026

Diabetes (Type 2)
Weekly Report

This week's data 35 new clinical trials registered across 10 countries, with 1,966 trials actively recruiting patients worldwide.
Week of November 9 – November 16, 2026
  • 35 new clinical trials registered across 10 countries.
  • 1,966 trials actively recruiting patients worldwide.
  • Notable trial: Cardiopulmonary Exercise Active Health Cohort Study (10000 patients).
  • 1,381 new research papers published.
  • Top cited: "Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes acro..." (Nature Communications, 35 citations).
  • Drug safety: Most reported effect across tracked medications (metformin, semaglutide, sitagliptin, empagliflozin, insulin glargine) was Off Label Use.
  • No active drug recalls for tracked medications this week.

The week in numbers

Figures · November 9 – November 16, 2026
New Trials This Week
35.
registered Nov 9–Nov 16
Recruiting Now
1,966
active trials seeking patients
Countries
10
with active trials this week
Papers Published
1,381
new studies this week
Phase 3 Trials
5
late-stage trials this week
Fig. 01

Trials by country

Count · November 9 – November 16, 2026
United States
140
China
46
Germany
34
Japan
31
Poland
29
Turkey (Türkiye)
21
Portugal
20
United Kingdom
19
Saudi Arabia
18
South Korea
18
0 35 70 105 140
total
Fig. 02

Trials by phase

Distribution · November 9 – November 16, 2026

New clinical trials registered this week for Diabetes (Type 2). Each trial links to its full record on ClinicalTrials.gov where you can find eligibility criteria, locations, and contact information.

§ 03

This week's new registrations

Click any header to sort

35 trials registered for Diabetes (Type 2). Each links to its full record on ClinicalTrials.gov.

# Trial ↓ Phase ↕ Status ↕ Enrollment ↕ Country ↕
01 Ocular Changes in Patients Using Tirzepatide or Semaglutide Diabetes (Type 2) · Istanbul University (NCT07924618) Other Recruiting 40 Turkey (Türkiye)
02 Fulvic Acid Supplementation and Metabolic Syndrome Diabetes (Type 2) · Arizona State University (NCT07927283) Other Recruiting 60 United States
03 Effect of Proliverenol on Liver Fat and Insulin Resistance in Type 2 Diabetes Diabetes (Type 2) · Universitas Sriwijaya (NCT07928661) Phase 2 Recruiting 50 Indonesia
04 A Study of Brenipatide (LY3537031) Comparing Two Formulations in Healthy Adults Diabetes (Type 2) · Xavier University of Louisiana. (NCT07927309) Other Not Yet Recruiting 180 N/A
05 One-Minute Exercise Snacks and Daytime Glucose in Adults With Type 2 Diabetes Diabetes (Type 2) · Capital University of Physical Education and Sports, China (NCT07930065) Other Completed 40 China
06 Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes Diabetes (Type 2) · German Diabetes Center (NCT07926152) Other Not Yet Recruiting 94 Germany
07 Intensive Glycemic Control Combined With Brolucizumab for Diabetic Macular Edema Diabetes (Type 2) · The Fourth Affiliated Hospital of Zhejiang University School of Medicine (NCT07937163) Other Not Yet Recruiting 100 N/A
08 Improving the Recruitment and Retention in the Intensive Diabetes Prevention Program at Hong Kong in District Health Centers Diabetes (Type 2) · The Hong Kong Polytechnic University (NCT07930195) Other Not Yet Recruiting 170 N/A
09 Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion Diabetes (Type 2) · The University of Texas Health Science Center at San Antonio (NCT07925801) Phase 2 Not Yet Recruiting 34 United States
10 Stress Coping Training for Nurses and Diabetes Control Diabetes (Type 2) · The New Model of Care, Hail Health Cluster (NCT07933159) Other Not Yet Recruiting 204 Saudi Arabia
11 Fuling Yunhua Granules and Dihuang Baoyuan Granules in Adults With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Therapy Diabetes (Type 2) · Beijing Supreme Life Pharmaceutical Technology Co., Ltd. (NCT07929350) Phase 2 Not Yet Recruiting 150 China
12 Cardiopulmonary Exercise Active Health Cohort Study Diabetes (Type 2) · Peking University Third Hospital (NCT07935187) Other Recruiting 10,000 China
13 A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both Diabetes (Type 2) · Novo Nordisk A/S (NCT07931599) Phase 3 Not Yet Recruiting 1,060 United States
14 Silica-Based Wound Treatment (Curi01) Plus Standard Care Versus Standard Care Alone for Chronic Diabetic Foot Wounds Diabetes (Type 2) · Cutempa Medical AG (NCT07937215) Other Recruiting 280 Germany
15 A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise Diabetes (Type 2) · Novo Nordisk A/S (NCT07931495) Phase 3 Not Yet Recruiting 200 United States
16 Acute Blood Flow Restriction Walking on Immune Cell Phenotype and Function Diabetes (Type 2) · University of British Columbia (NCT07928531) Other Recruiting 20 Canada
17 Continuous Glucose Monitoring on Dietary Choices and Cardiometabolic Health in Older Adults Without Diabetes Diabetes (Type 2) · Texas Woman's University (NCT07934797) Other Completed 21 United States
18 Tailored Education for Aging and Cognitive Health: A Health Behavior Change Intervention for Midlife Adults at Risk for Alzheimer's Disease and Related Dementias Diabetes (Type 2) · Rhode Island Hospital (NCT07933367) Other Not Yet Recruiting 280 United States
19 Effects of Adjunctive Melatonin Gel in Type II Diabetics With Stage III-IV Periodontitis Diabetes (Type 2) · Badr University (NCT07928752) Other Not Yet Recruiting 32 Egypt
20 24-hour Clear Liquid Diet vs. Standard Fasting for Upper Gastrointestinal Endoscopy in Patients Taking Agonists of the GLP-1 Receptor Diabetes (Type 2) · Portuguese Oncology Institute, Coimbra (NCT07929233) Other Not Yet Recruiting 250 Portugal
21 Continuous Glucose Monitoring Parameter and Oral Glucose Tolerance Testing (OGTT) Parameters in Children and Young Adults With Cystic Fibrosis (CF) Diabetes (Type 2) · Northwell Health (NCT07930884) Other Recruiting 30 United States
22 Muscle Relaxation Technique on Neuropathic Pain Diabetes (Type 2) · Al-Zaytoonah University of Jordan (NCT07935499) Other Completed 96 Jordan
23 Preoperative Gastric Ultrasound to Assess Stomach Contents and Aspiration Risk in Patients With Diabetes Diabetes (Type 2) · Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (NCT07929207) Other Not Yet Recruiting 130 Turkey (Türkiye)
24 Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes Diabetes (Type 2) · Pamukkale University (NCT07924436) Other Recruiting 30 Turkey (Türkiye)
25 AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both Diabetes (Type 2) · Novo Nordisk A/S (NCT07931573) Phase 3 Not Yet Recruiting 1,200 United States
26 AI Chatbot Mobile App for Self-Management in Type 2 Diabetes Diabetes (Type 2) · Alexandria University (NCT07926074) Other Not Yet Recruiting 120 Egypt
27 Mindfulness Program for Blood Sugar Control, Heart Rate Variability, Anxiety, and Depression in Type 2 Diabetes Diabetes (Type 2) · Universitas Sebelas Maret Hospital (NCT07936357) Other Completed 28 Indonesia
28 Prevalence and Factors Associated With Depression Among Children and Adolescents With Type 1 Diabetes Mellituss Diabetes (Type 2) · Asmaa Abdelnasser Madian (NCT07925164) Other Not Yet Recruiting 100 N/A
29 Immunological Signatures of MASLD and MASH in Patients With Type 1 Diabetes Diabetes (Type 2) · Assistance Publique - Hôpitaux de Paris (NCT07927647) Other Not Yet Recruiting 1,000 France
30 Efficacy, Safety and Cardiovascular Protection of Mazdutide in Type 1 Diabetes Diabetes (Type 2) · Peking University People's Hospital (NCT07924553) Other Not Yet Recruiting 182 N/A
31 A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both Diabetes (Type 2) · Novo Nordisk A/S (NCT07931547) Phase 3 Not Yet Recruiting 450 United States
32 Alpha-Lipoic Acid Added to Dapagliflozin and Insulin Resistance in Type 2 Diabetes Diabetes (Type 2) · Fayoum University (NCT07934225) Phase 3 Not Yet Recruiting 70 Egypt
33 Cardiovascular And Dementia Risk in diabeTes: the Role of Nox2- Related Oxidative Stress. Diabetes (Type 2) · Neuromed IRCCS (NCT07928453) Other Recruiting 250 Italy
34 Ultrasound-Guided Thoracolumbar Fascia Injection for Chronic Low Back Pain in Patients With Type 2 Diabetes Diabetes (Type 2) · Hatice Zehra FERHATLAR (NCT07927530) Other Recruiting 60 Turkey (Türkiye)
35 Ramadan Nutrition Plan (RNP) Education for Glycaemic Control in Older Adults With Type 2 Diabetes in Yogyakarta Diabetes (Type 2) · Universiti Putra Malaysia (NCT07932210) Other Not Yet Recruiting 133 Indonesia
§ 04

Adverse event reports

FDA FAERS · 2025 data

Adverse drug event reports compiled from the FDA's FAERS database for medications commonly prescribed for Diabetes (Type 2). These reports reflect what patients and healthcare providers have reported — they do not confirm a drug caused the effect.

Reports by drug

DrugTop effectCount
metformin Diarrhoea 2,273
semaglutide Nausea 2,980
sitagliptin Nausea 332
empagliflozin Nausea 836
insulin glargine Off Label Use 4,782

Recalls & safety notices

§ 05 · 0 items this week

FDA drug recall notices for medications related to Diabetes (Type 2). If your medication is listed, contact your pharmacist or visit fda.gov/safety/recalls for guidance. No recall listed does not guarantee safety — always consult your healthcare provider.

No active drug recalls for tracked medications this period.

§ 06

Published research

1,381 papers

Recently published peer-reviewed studies related to Diabetes (Type 2), sourced from PubMed and Semantic Scholar. Click any title to read the full paper, or expand the abstract for a quick summary.

# Study Journal Date Source
01 Regulatory T-Cell dysfunction in FOXP3-associated IPEX and selected phenocopies: mechanisms, diagnosis, and treatment. Akhtar MA et al. 10.1007/s11033-026-13170-2
View abstract

Regulatory T cells (Tregs) maintain peripheral immune tolerance, with FOXP3 directing much of their differentiation and suppressive activity. Pathogenic FOXP3 variants cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Although often described as Treg deficiency, IPEX can occur despite preserved circulating Treg numbers and detectable FOXP3 expression. This narrative review examines how FOXP3 variants disrupt regulatory function and compares IPEX with selected genetic disorders involving BACH2, IL2RA, STAT5B, CTLA4 or LRBA. Structural and epigenetic findings are considered alongside their implications for diagnosis and treatment. The disorders are grouped by transcriptional regulation, IL-2-dependent homeostasis and checkpoint function; an IPEX-like presentation is distinguished from a defined Tregopathy. Genetic testing is central to diagnosis, while immunophenotyping and selected functional or epigenetic studies provide supporting evidence. In severe disease, investigation, stabilization and hematopoietic stem cell transplantation (HSCT) assessment should proceed together. HSCT remains an established potentially curative treatment. Cellular and genetic therapies are at different stages of development, from preclinical studies to early human investigation, and must be assessed individually. Comparisons with other genetic disorders and common autoimmunity help explain shared biology, but treatment findings cannot be assumed to apply equally to IPEX.

Molecular biology reports 2026 Nov 15 PubMed
02 Spatiotemporal Distribution and Projections to 2050 of the Disease Burden of Early-Onset Chronic Diseases Attributable to Low Physical Activity: A Global Burden of Disease Study. Wang Y et al. 10.1186/s40798-026-01141-7
View abstract

BACKGROUND: Low physical activity is a modifiable risk factor for non-communicable diseases, but its contribution to early-onset chronic disease burden remains insufficiently quantified. We estimated global, regional, and national burdens of selected early-onset chronic diseases attributable to low physical activity from 1990 to 2021 and projected burden to 2050. METHODS: Using Global Burden of Disease (GBD) 2021 estimates for 204 countries and territories, we quantified disability-adjusted life years (DALYs) and age-standardized DALY rates (ASDRs) attributable to low physical activity for cancer, cardiovascular disease, diabetes mellitus, and chronic kidney disease among adults aged 25-49 years. Because GBD low physical activity exposure estimates are mainly modeled for adults aged ≥25 years, individuals aged 15-24 years were not included in the risk-attributable analyses. Trends, Socio-demographic Index (SDI)-related inequality, and future burden were assessed using estimated annual percentage changes (EAPCs), inequality indices, and Bayesian age-period-cohort modeling. RESULTS: Global DALYs attributable to low physical activity increased by 94.2%, from 686,847 in 1990 to 1.33 million in 2021. ASDR increased from 25.3 to 33.8 per 100,000 population (EAPC = 0.84; 95% confidence interval (CI) 0.70-0.97). Diabetes mellitus and chronic kidney disease showed the fastest ASDR increases, whereas cardiovascular disease and cancer showed no statistically robust trends. In 2021, regional ASDRs varied more than 11-fold, were highest in Oceania, and were higher among females and in middle-SDI settings. Absolute inequality widened, while relative inequality remained uncertain. By 2050, DALYs are projected to reach 1.76 million. CONCLUSION: Early-onset chronic disease burden attributable to low physical activity has increased substantially and unevenly. Targeted physical activity strategies for young and working-age adults are needed to reduce preventable future burden.

Sports medicine - open 2026 Nov 15 PubMed
03 Newly Diagnosed Autoimmune Type 1 Diabetes Presenting With Severe Diabetic Ketoacidosis in a 92-Year-Old Woman: A Rare Diagnosis in the Tenth Decade of Life. Mohd Saleem FS et al. 10.7759/cureus.119616
View abstract

New-onset type 1 diabetes mellitus is rare in very elderly patients. We describe a 92-year-old woman with no previous diagnosis of diabetes who presented with a one-week history of polyuria, polydipsia, generalized malaise, diarrhea, and vomiting, alongside a one-month history of unintentional weight loss and reduced appetite. On admission, she was found to be in severe diabetic ketoacidosis (DKA), meeting Joint British Diabetes Societies severity criteria on the basis of blood ketones reported as "HI" (exceeding the >6 mmol/L threshold); arterial pH was 7.24, bicarbonate 19.2 mmol/L, and lactate 3.56 mmol/L. Blood glucose was above the measurable range, also reported as "HI." Contrast-enhanced computed tomography (CT) of the abdomen and pelvis was later performed to exclude an underlying secondary cause of hyperglycemia, including pancreatic pathology or malignancy, and revealed no significant abnormalities. Positive anti-glutamic acid decarboxylase (anti-GAD) antibodies and a low C-peptide level supported a diagnosis of autoimmune, insulin-deficient type 1 diabetes. She was managed according to DKA protocol, and following resolution of DKA, she was discharged with diabetes and primary care follow-up. This case highlights the diagnostic value of autoimmune antibody testing in elderly patients presenting with severe DKA, given that age-based assumptions about diabetes subtype may otherwise lead to misclassification and inappropriate management.

Cureus 2026 Nov PubMed
04 Cryptogenic Invasive Klebsiella pneumoniae Liver Abscess Syndrome with Occult Colon Cancer: A Case Report. Wang N et al. 10.2147/IDR.S653635
View abstract

BACKGROUND: Invasive liver abscess syndrome (IKLAS) describes liver abscess with extrahepatic metastatic infection. Although the syndrome is associated with hypervirulent (hvKP), its clinical presentation alone does not confirm hypervirulence. Occult colorectal malignancy may be identified during evaluation of apparently cryptogenic infection. CASE PRESENTATION: A 75-year-old man presented with intermittent fever for more than 1 month and right upper abdominal pain. Imaging revealed multiple hepatic abscesses and pulmonary lesions compatible with metastatic infection. was isolated from blood and sputum cultures, supporting a clinical diagnosis of IKLAS. Hypervirulence was clinically suspected but not microbiologically confirmed because capsular serotyping and virulence-gene testing were not performed. The patient had no history of diabetes mellitus or biliary tract disease. Abdominal CT showed irregular wall thickening at the hepatic flexure, and colonoscopy with biopsy confirmed moderately to poorly differentiated adenocarcinoma. Piperacillin-tazobactam and moxifloxacin were associated with clinical improvement and radiologic regression; percutaneous drainage was deferred because of incomplete abscess liquefaction. After infection control, he underwent laparoscopic radical right hemicolectomy (pathological stage pT3N0Mx). No recurrence or distant metastasis was detected at the 9-month postoperative follow-up. CONCLUSION: This case illustrates that apparently cryptogenic IKLAS may be an initial clinical clue to occult colon cancer. Individualized colorectal evaluation may be considered, particularly in patients without common predisposing factors or with suspicious clinical or imaging findings. This single case does not establish causality or support universal screening.

Infection and drug resistance 2026 PubMed
05 Probiotics and Prebiotics in Restoring Gastrointestinal Microbiota Dysbiosis: Emerging Alternatives to Antibiotic Therapy. Goa T et al. 10.1155/ijfo/6956918
View abstract

The human gastrointestinal (GI) microbiota is a complex and dynamic microbial ecosystem that plays a fundamental role in maintaining host metabolism, immune homeostasis, intestinal barrier integrity, and protection against pathogenic microorganisms. Disruption of this microbial community, known as gut dysbiosis, has been implicated in the pathogenesis of numerous GI and systemic diseases, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), infection, obesity, type 2 diabetes mellitus, colorectal cancer, and nonalcoholic fatty liver disease. Although antibiotics remain indispensable for the treatment of bacterial infections, their indiscriminate use frequently disrupts gut microbial composition, reduces microbial diversity, promotes opportunistic pathogen overgrowth, and accelerates the emergence of antimicrobial resistance. These limitations have stimulated increasing interest in microbiota-targeted interventions as safer and more sustainable therapeutic strategies. Probiotics and prebiotics have emerged as promising approaches for restoring gut microbial homeostasis through complementary mechanisms. Probiotics inhibit pathogen colonization, enhance intestinal barrier function, produce antimicrobial metabolites, and modulate host immune responses. Prebiotics selectively stimulate the growth and metabolic activity of beneficial microorganisms, promoting the production of short-chain fatty acids (SCFAs) that support intestinal and systemic health. Increasing evidence from experimental studies, randomized clinical trials, and meta-analyses demonstrates that these microbiota-directed interventions can reduce antibiotic-associated diarrhea, improve symptoms of IBD and IBS, enhance eradication, decrease recurrence of infection, and contribute to the management of several metabolic disorders. Despite these promising findings, important challenges remain regarding strain specificity, optimal dosage, treatment duration, product standardization, regulatory oversight, and interindividual variability in treatment response. Emerging advances in metagenomics, metabolomics, artificial intelligence, and precision medicine are facilitating the development of personalized microbiome-based therapies that may further enhance clinical outcomes. This review critically summarizes the current understanding of GI microbiota dysbiosis, discusses the mechanisms through which probiotics and prebiotics restore microbial balance, evaluates their clinical applications as alternatives or adjuncts to antibiotic therapy, and highlights existing challenges and future research directions for microbiome-based therapeutics.

International journal of food science 2026 PubMed
06 Diagnostic accuracy of peak vein velocity ratio for innominate vein stenosis in haemodialysis patients with long-term non-cuffed right internal jugular catheters. Pratama D et al. 10.1177/1742271X261500592
View abstract

OBJECTIVE: To evaluate the diagnostic accuracy of ultrasound-derived peak vein velocity ratio for detecting central vein stenosis in the innominate vein resulting from long-term non-cuffed double-lumen haemodialysis catheters. METHODS: A cross-sectional study was conducted on haemodialysis patients with right internal jugular vein catheters. All subjects underwent duplex ultrasound to calculate peak vein velocity ratio, defined as the ratio of peak velocity in the innominate vein to the pre-stenotic internal jugular vein. Venography was performed as the gold standard. RESULTS: Of 50 patients analysed, innominate vein stenosis prevalence was 68%. Diabetes mellitus was significantly associated with stenosis (odds ratio = 5.16;  = 0.049). An innominate-to-internal jugular vein peak vein velocity ratio cutoff of ⩾1.65 identified innominate vein stenosis (>30% luminal narrowing) with 97.1% sensitivity, 56.2% specificity, and an area under the curve of 0.71. CONCLUSION: Peak vein velocity ratio shows high sensitivity and negative predictive value as a screening tool for catheter-related innominate vein stenosis. A cutoff of 1.65 makes significant stenosis unlikely when not exceeded, supporting a possible role as a non-invasive triage step before venography in resource-limited settings, pending external validation.

Ultrasound (Leeds, England) 2026 Nov 11 PubMed
07 Smart insulin pens with integrated bolus calculator vs tracking-only connected insulin pens in adults with diabetes on multiple daily injections: a multicentre randomised controlled trial. Moon SJ et al. 10.1007/s00125-026-06914-z
View abstract

AIMS/HYPOTHESIS: Connected insulin pens (CIPs) have emerged as a promising tool for diabetes management with multiple daily injections (MDI), but evidence supporting the incremental benefit of integrated bolus calculator functionality (smart insulin pens [SIPs]) over tracking-only CIPs remains lacking. We evaluated the efficacy and safety of SIPs with bolus calculator compared with tracking-only CIPs in adults with diabetes on MDI. We hypothesised that SIPs with bolus calculator would improve glycaemic management compared with tracking-only CIPs. METHODS: In this multicentre, open-label, randomised controlled trial conducted at nine medical centres in South Korea, we recruited adults aged 19-74 years with type 1 or type 2 diabetes on MDI therapy. Participants with HbA 58-108 mmol/mol (7.5-12.0%) were randomly assigned (1:1) using computer-generated block randomisation stratified by diabetes type (sequence generated by an independent statistician) to SIP with bolus calculator or tracking-only CIP for 12 weeks. All participants used continuous glucose monitoring (CGM). The primary outcome was the change in HbA from baseline to week 12. Secondary outcomes included CGM metrics, insulin dosing behaviour and safety. RESULTS: A total of 120 participants were randomised to the SIP group (n=60) or the tracking-only CIP group (n=60); their mean (SD) age was 50.8 (14.8) years, 53 (44.2%) had type 1 diabetes and mean (SD) HbA was 69 (12) mmol/mol (8.5% [1.1%]). Of these, 116 were included in the modified intention-to-treat analysis. HbA decreased more with SIP than with tracking-only CIP (adjusted mean difference -3.39 mmol/mol [-0.31%]; 95% CI -6.45, -0.22 mmol/mol [-0.59%, -0.02%]; p=0.036). Time in range (3.9-10.0 mmol/l) improved significantly with SIP (57.2% vs 50.8%; adjusted mean difference 6.58%; 95% CI 1.52%, 11.64%; p=0.012). SIP users had fewer missed bolus doses (3.4 vs 3.7 times/day; p=0.020) and higher bolus frequency (3.2 vs 2.8 times/day; p=0.011). No severe hypoglycaemia or diabetic ketoacidosis occurred in either group. CONCLUSIONS/INTERPRETATION: In this randomised controlled trial of adults with suboptimally controlled diabetes on MDI, SIP with bolus calculator significantly improved glycaemic management and dosing behaviour compared with tracking-only CIP. TRIAL REGISTRATION: ClinicalTrials.gov NCT06406439. FUNDING: This study was supported by G2E Co., Ltd, Korea and Huons Co., Ltd, Korea.

Diabetologia 2026 Nov 14 PubMed
08 Associations between diabetic neuropathy and bone density and bone microarchitecture in type 2 diabetes: The Deep Phenotyping Study. Graversen JL et al. 10.1007/s00198-026-08301-1
View abstract

PURPOSE: Diabetic neuropathy may contribute to skeletal fragility through sensorimotor and autonomic dysfunction. We investigated associations of peripheral and autonomic neuropathy with bone density, microarchitecture, and material properties in individuals with type 2 diabetes stratified by age. METHODS: In this cross-sectional study, individuals with type 2 diabetes with (n = 50, mean age 67.4 years) and without (n = 73, mean age 62.2 years) diabetic neuropathy underwent assessment of bone structure and quality using dual-energy X-ray absorptiometry with trabecular bone score, high-resolution peripheral computed tomography, and microindentation, alongside evaluation of neuropathy and autonomic function. Associations were assessed using multivariable linear regression adjusted for age, sex, and BMI, with age-stratified analyses ( < 65 and ≥65 years). RESULTS: In individuals < 65 years, neuropathy was associated with markedly lower areal bone mineral density at the total hip (β =-0.15 g/cm, 95% CI -0.24 to-0.06), and femoral neck (β =-0.18 g/cm², -0.26 to -0.09), and with lower TBS (β =-1.56, -2.23 to -0.89). At the tibia, neuropathy was associated with lower total, cortical and trabecular volumetric bone mineral density, lower trabecular bone volume fraction, and higher cortical porosity. At the radius, lower cortical volumetric bone mineral density and lower trabecular number were observed. No significant associations were observed for Bone Material Strength index or in individuals ≥ 65 years. CONCLUSION: In individuals with type 2 diabetes <65 years, diabetic neuropathy is associated with lower bone density and differences in cortical and trabecular microarchitecture. These findings suggest neuropathy may be associated with impaired bone quality in younger adults with type 2 diabetes.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026 Nov 14 PubMed
09 Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review. Muknickas D et al. 10.1186/s12903-026-10305-6
View abstract

OBJECTIVES: To map the systemic and oral adverse events (AEs) of semaglutide reported in randomized controlled trials (RCTs). DATA: This scoping review was conducted following the PRISMA-ScR guidelines. Only english-language and RCTs were considered. SOURCES: A literature search was conducted in PubMed, Scopus, and Web of Science from 2019 until 2025. STUDY SELECTION: Of 630 identified records (300 in PubMed, 312 in Scopus, and 18 in Web of Science), 12 studies were included after screening. The review identified systemic AEs of semaglutide, primarily gastrointestinal events like nausea (12 studies) and diarrhea (11 studies). Less frequent effects included pancreatitis (5 studies), hepatobiliary (3 studies) and gallbladder disease (3 studies), dental caries (1 study) and dry mouth (1 study). Subcutaneous administration predominating (7 studies), followed by oral (3) and mixed routes (2), over treatment durations of 21-68 weeks and 4-9 weeks of follow-up. Additionally, systemic events such as nasopharyngitis (5 studies), COVID-19 (5 studies), and metabolic or nutrition-related disorders were reported in all 12 studies. Importantly, none of the included studies directly investigated oral or dental outcomes. CONCLUSIONS: Semaglutide demonstrated an overall favorable safety profile in the included randomized controlled trials, with adverse events predominantly gastrointestinal. However, the RCTs did not provide direct evidence regarding oral health outcomes. Therefore, the available evidence is insufficient to draw conclusions about oral adverse events associated with semaglutide, highlighting the need for randomized clinical trials specifically designed to assess oral health outcomes in patients receiving GLP-1 receptor agonists.

BMC oral health 2026 Nov 14 PubMed
10 Angioedema risk with DPP4 inhibitors by concomitant RAAS inhibitor use. Alkhalaf A et al. 10.1136/bmjdrc-2026-006377 BMJ open diabetes research & care 2026 Nov 13 PubMed
11 Fenofibrate and diabetic retinopathy: an updated systematic review and meta-analysis of randomized controlled trials. Dogru E et al. 10.1016/j.diabres.2026.113669
View abstract

AIMS: To assess fenofibrate effects on diabetic retinopathy (DR) progression and need for retinal treatment. METHODS: PubMed, Embase, and Scopus were searched through June 9, 2026, for randomized trials comparing oral fenofibrate with placebo in adults with type 1 or type 2 diabetes and at least two years of follow-up. The primary outcome was a composite of DR progression or need for retinal treatment. Odds ratios (OR) were pooled using random-effects models. RESULTS: Four trials (20,655 participants) were included; three (3,756) contributed to the primary outcome. Fenofibrate reduced the composite outcome (OR 0.67, 95% CI 0.56-0.81; I = 0%), incident macular edema (0.47, 0.29-0.76; I = 0%) and need for retinal laser (0.75, 0.65-0.87; I = 7%). DR progression on imaging was reduced (0.72, 0.58-0.89; I = 0%), but not when FIELD one-step progression was used (0.80, 0.60-1.07). Moderate vision loss (0.99, 0.83-1.18; I = 0%) and all-cause mortality (1.01, 0.87-1.17; I = 26%) did not differ. Subgroup analyses by diabetes type and baseline retinopathy were underpowered. CONCLUSIONS: Fenofibrate reduces the composite of DR progression or need for retinal treatment over up to five years of follow-up, without a demonstrated effect on moderate vision loss.

Diabetes research and clinical practice 2026 Nov 14 PubMed
12 Cumulative exposure and longitudinal changes in KDM age Acceleration-Integrated insulin resistance indices in relation to incident cardiometabolic multimorbidity among individuals with Cardiovascular-Kidney-Metabolic syndrome stages 0-3: A prospective cohort study. Tan MY et al. 10.1016/j.diabres.2026.113665
View abstract

BACKGROUND: Insulin resistance (IR) and biological aging may jointly contribute to cardiovascular-kidney-metabolic (CKM) syndrome progression, but longitudinal evidence for cardiometabolic multimorbidity (CMM) is limited. METHODS: Using the China Health and Retirement Longitudinal Study, we included participants with CKM stages 0-3 who were free of CMM. KDM age acceleration was integrated with TyG and related IR indices. Cox models assessed baseline and Wave 3 levels, cumulative exposure, annualized change, and longitudinal exposure profiles in relation to incident CMM. Predictive performance was evaluated using the C-index, time-dependent AUC, Brier score, and reclassification metrics. RESULTS: Higher baseline and Wave 3 levels of all KDM age acceleration-integrated IR indices were associated with higher CMM risk when modeled continuously, whereas associations with cumulative exposure were less consistent. Per 1-SD increase, the adjusted HRs were 1.28, 1.24, and 1.21 for baseline, Wave 3, and cumulative KDM age acceleration × TyG, respectively. In exploratory longitudinal exposure-profile analyses, higher-level profiles were associated with increased CMM risk for several indices, although these profiles mainly reflected relative exposure levels across the two assessments rather than distinct temporal trajectories. The cumulative KDM age acceleration × TyG model achieved an optimism-corrected C-index of 0.762 and a 5-year AUC of 0.770. CONCLUSIONS: Higher single-time-point levels of KDM age acceleration-integrated IR indices were associated with incident CMM, whereas associations with cumulative exposure were less consistent and annualized changes were not significantly associated with risk. Incremental predictive performance was modest.

Diabetes research and clinical practice 2026 Nov 14 PubMed
13 Associations between U-HP, TyG-BMI, TG/Cys-C and albuminuria in individuals with type 2 diabetes mellitus: A cross-sectional study. Huang Y et al. 10.1016/j.diabres.2026.113666
View abstract

AIMS: To investigate the correlations of urinary haptoglobin (U-HP), triglyceride-glucose-body mass index (TyG-BMI), and triglyceride/cystatin C (TG/Cys-C) with albuminuria in individuals with type 2 diabetes mellitus (T2DM). METHODS: A total of 174 hospitalized T2DM patients were retrospectively enrolled and divided into non-albuminuria (n = 88) and albuminuria (n = 86) groups according to the urinary albumin-to-creatinine ratio (UACR). Spearman correlation, multivariate logistic regression, and characteristic (ROC) curve analyses were performed. Internal bootstrap validation with 1000 resamples was conducted to assess model optimism. RESULTS: U-HP and TyG-BMI were higher, while TG/Cys-C was lower in the albuminuria group (all P < 0.05). U-HP was correlated with the UACR (r = 0.57) and was identified as an independent factor associated with albuminuria (OR = 1.233 per 100 μg/L increase;95%CI: 1.045-1.455; P = 0.013). The AUC of U-HP was 0.755 (95%CI: 0.682-0.827). The fully adjusted model including clinical variables and medication use achieved an AUC of 0.867 (95%CI: 0.813-0.921). CONCLUSION: U-HP is independently associated with albuminuria in hospitalized T2DM patients with moderate discriminative value and high specificity. However, owing to the cross-sectional design and the inherent correlation between U-HP and UACR, these findings reflect associations rather than predictions and require validation in prospective cohort studies.

Diabetes research and clinical practice 2026 Nov 14 PubMed
14 Mapping the Molecular Interaction Profile of 5-(1,3,4-Oxadiazol-2-yl)-Substituted Pyrimidine Hybrids in Diabetes Mellitus: Synthetic Development, Enzyme Kinetics, Molecular Recognition, In Vivo Toxicology and Therapeutic Translation. Khowdiary MM 10.1016/j.cbi.2026.112428
View abstract

Diabetes mellitus is a major metabolic disorder characterized by persistent hyperglycemia and remains a significant therapeutic challenge. Inhibition of α-amylase and α-glucosidase, key enzymes involved in carbohydrate digestion, represents an effective strategy for controlling postprandial glucose levels. In the present study, a novel series of pyrimidine-oxadiazole hybrid derivatives was designed, synthesized, structurally characterized, and evaluated using complementary experimental and computational approaches. The synthesized compounds exhibited promising inhibitory activity against both enzymes, with compound 5 having IC = 5.20 ± 0.10 μM and 5.90 ± 0.30 μM for α-amylase and α-glucosidase, respectively,emerging as the most potent derivative against α-amylase and α-glucosidase, showing greater activity than the reference drug acarbose. Structure-activity relationship analysis revealed that the electronic and steric characteristics of substituents substantially influenced enzyme inhibitory activity. Molecular docking demonstrated favorable binding orientations. Density functional theory (DFT) calculations provided insights into the electronic properties, frontier molecular orbitals, and chemical reactivity of the active derivatives. Furthermore, in silico ADMET profiling indicated favorable drug-like and pharmacokinetic characteristics. Overall, these findings identify compound 5 and the pyrimidine-oxadiazole scaffold as promising frameworks for further development of dual α-amylase/α-glucosidase inhibitors.

Chemico-biological interactions 2026 Nov 14 PubMed
15 Papillary Necrosis Masquerading as a Stone. Palanivel P et al. 10.1016/j.kint.2026.10.027 Kidney international 2026 Nov 14 PubMed
16 Endogenous hypercortisolism and cardio-liver-metabolic dysfunctions: from pathogenesis to the effects of therapeutic strategies targeting hypercortisolism. Pivonello R et al. 10.1016/j.metabol.2026.156845
View abstract

Endogenous hypercortisolism, namely Cushing's syndrome (CS) is a rare but severe endocrine disorder caused by chronic exposure to excess glucocorticoids and characterized by substantial morbidity and increased mortality. Persistent hypercortisolism profoundly affects multiple cardiovascular and metabolic pathways, leading to a broad spectrum of cardio-liver-metabolic complications including arterial hypertension, cardiac and vascular remodelling, thrombotic diathesis, hepatic steatosis, visceral obesity, impaired glucose metabolism, and dyslipidemia. These alterations arise from complex interactions between direct glucocorticoid effects on target tissues and indirect mechanisms, mainly involving insulin resistance, endothelial dysfunction, chronic inflammation, and altered lipid metabolism. The primary therapeutic objective in CS is the normalization of cortisol excess through surgery, radiotherapy, or medical therapy, namely pharmacological treatment. In recent years, the availability of medical drugs targeting pituitary ACTH secretion, adrenal steroidogenesis, or glucocorticoid receptor signalling has expanded therapeutic options for patients with CS, especially with persistent or recurrent disease. Beyond biochemical control of hypercortisolism, namely normalization of urinary free cortisol (UFC) (UFC ≤ upper limit of normal), accumulating evidence suggests that these treatments may improve several cardiometabolic manifestations associated with cortisol excess. However, although remission of hypercortisolism leads to significant clinical improvement, complete normalization of cardio-liver-metabolic alterations is not consistently achieved. Many patients continue to exhibit persistent cardiovascular and metabolic abnormalities even after long-term biochemical remission, highlighting the need for active long-term monitoring and multidisciplinary management to prevent disease progression and optimize long-term outcomes. This mini-review briefly outlines the pathogenesis of cardio-liver-metabolic dysfunctions and discusses the potential effects of currently available therapeutic strategies targeting hypercortisolism on these comorbidities.

Metabolism: clinical and experimental 2026 Nov 14 PubMed
17 Mu (μ) opioid receptors (MOP) in food addiction. Meir K et al. 10.1016/j.pnpbp.2026.112006
View abstract

The 21st century has been plagued with obesity worldwide, mostly in developed countries where access to food is plentiful. Obesity can be a precursor for many other diseases, such as hypertension, hyperlipidemia, type 2 diabetes mellitus, etc. Therefore, the underlying mechanism of obesity must be understood to cease its progression to other morbidities. There are two aspects of food intake: homeostatic feeding, which regulates energy intake so that the organism has a balanced energy level, and the hedonic feeding, which often causes the organism to consume food greater than its metabolic needs due to the food palatability and motivational alterations. The opioid system, specifically the mu (μ) opioid receptor (MOP), has been heavily implicated in playing an important role in both of these feeding processes. This article aims to review the literature regarding the role of the MOP on different aspects of food intake, including homeostatic and hedonic feeding, binge eating, as well as the existence of sexual dimorphism in food intake regulation via MOP.

Progress in neuro-psychopharmacology & biological psychiatry 2026 Nov 14 PubMed
18 Mitochondrial Fatty Acid Oxidation Dysregulation in Metabolic Dysfunction-Associated Steatotic Liver Disease: Mechanistic Roles and Emerging Diagnostic and Therapeutic Advances. Wang SY et al. 10.1016/j.phrs.2026.109732
View abstract

Metabolic dysfunction-associated steatotic liver disease is a chronic metabolic liver disorder driven by the convergent effects of obesity, insulin resistance, lipid overload, gut-liver axis disruption, and immune inflammation. Mitochondrial fatty acid oxidation is central to the disposal of excess fatty acids and the maintenance of hepatocellular energy homeostasis; under sustained metabolic stress, however, this process can shift from an adaptive response to a molecular hub for incomplete oxidation, oxidative injury, inflammatory amplification, and fibrotic progression. This review examines fatty acid uptake and activation, carnitine-dependent transport, sequential β-oxidation, the tricarboxylic acid cycle, electron transfer, mitochondrial quality control, and immunometabolic crosstalk, and explains how diet, circadian disruption, aging, gut dysbiosis, drug exposure, and genetic susceptibility destabilize oxidative homeostasis through defined molecular pathways. From a translational perspective, we propose a functional-endotype framework that integrates imaging, acylcarnitine profiling, lipidomics, oxidative-damage markers, inflammatory and fibrotic indices, and genetic risk to guide stratified interventions targeting thyroid hormone signaling, peroxisome proliferator-activated receptors, incretin pathways, bile-acid signaling, fibroblast growth factors, energy-sensing networks, and precision nanomedicine.

Pharmacological research 2026 Nov 14 PubMed
19 QRICH1 promotes PDK4-dependent mitochondrial dysfunction and pyroptosis in diabetic cardiomyopathy. Sun M et al. 10.1016/j.cellsig.2026.113008
View abstract

BACKGROUND: Diabetic cardiomyopathy (DCM) is characterized by myocardial metabolic remodeling and inflammatory cell death, yet the transcriptional regulators linking metabolic stress to cardiomyocyte injury remain poorly defined. METHODS: Glutamine-rich protein 1 (QRICH1) expression was examined in hearts of mice with high-fat diet and streptozotocin-induced type 2 diabetes and in cardiomyocytes exposed to high glucose plus palmitic acid. QRICH1 transcriptional regulation of pyruvate dehydrogenase kinase 4 (PDK4) was verified by chromatin immunoprecipitation and dual-luciferase assays, and the effects of QRICH1 overexpression and PDK4 knockdown were assessed in vitro. Drug repurposing was performed by molecular docking and a drug affinity responsive target stability assay. RESULTS: QRICH1 was markedly upregulated in diabetic myocardium and under glucolipotoxic conditions. QRICH1 directly bound the PDK4 promoter and transactivated its expression. QRICH1 overexpression induced caspase-1-dependent pyroptosis, impaired mitochondrial respiration, and promoted cytosolic mitochondrial DNA (mtDNA) leakage with inflammatory signaling activation, and these changes were partially reversed by PDK4 knockdown. Vericiguat showed the strongest binding affinity for QRICH1 among screened cardiovascular drugs. In DCM mice, vericiguat significantly improved cardiac function, downregulated PDK4, and restored myocardial AKT phosphorylation. CONCLUSIONS: QRICH1 sustains PDK4 expression under glucolipotoxic stress, driving mitochondrial dysfunction, mtDNA release, and pyroptosis, and vericiguat represents a repurposing candidate for myocardial protection in DCM.

Cellular signalling 2026 Nov 14 PubMed
20 Quercetin-3-O-rhamnoside improves insulin sensitivity and attenuates pancreatic islet hypertrophy in high-fat diet-fed diabetic mice. Lamichhane R et al. 10.1016/j.bbrc.2026.154890
View abstract

Quercetin-3-O-rhamnoside (Q3R), a plant flavonoid glycoside, possesses anti-diabetic activity; however, its efficacy in modulating insulin resistance remains unclear. This study investigated the effect of Q3R on obesity-associated insulin resistance using C2C12 myotubes and high-fat diet (HFD)-fed obese mice. Insulin resistance was induced in differentiated C2C12 cells by palmitic acid (PA) treatment, while C57BL/6 mice were fed HFD (60% kcal from fat) for 10 weeks. Q3R treatment (20-30 μM) significantly enhanced insulin-stimulated glucose uptake in both normal and insulin-resistant myotubes. In HFD-induced diabetic mice, Q3R was orally administered daily for five weeks, and the OGTT performed approximately two weeks after the initiation of treatment showed enhanced glucose disposal, particularly at 15 mg/kg body weight. It also reduced HFD-associated increases in serum insulin, total cholesterol, and epididymal fat pad weight without affecting body weight. Q3R restored the insulin resistance-induced reduction in mRNA expression of insulin receptor substrate-1 (IRS-1) and glucose transporter 4 (GLUT4) in skeletal muscles. Furthermore, histological analyses suggested that Q3R may attenuate HFD-induced pancreatic islet hypertrophy and normalize insulin immunoreactivity. Collectively, these findings suggest that Q3R ameliorates insulin resistance and improves metabolic dysfunction in obesity-associated diabetic mice by enhancing insulin sensitivity and dampening pancreatic islet hypertrophy in high-fat diet-fed diabetic mice.

Biochemical and biophysical research communications 2026 Nov 12 PubMed
21 Associations of short and long sleep duration with multiple adverse health outcomes among ageing adults in South Africa. Pengpid S et al. 10.1016/j.sleep.2026.109365
View abstract

BACKGROUND: The aim of this study was to assess the longitudinal associations between short and long sleep duration with multiple adverse health outcomes (mortality, hypertension, cardiovascular disease, diabetes mellitus, functional limitations, depressive symptoms, loneliness, posttraumatic stress (PTSD) symptoms, impaired cognition, dynapenia, addominal obesity, dynapenic abdominal obesity, and general obesity) among community-residents 40 years and older, also broken down by sex. METHODS: Data from three waves of the "Health and Ageing in Africa: A Longitudinal Study of an INDEPTH Community in South Africa (HAALSI)" (2015-2022) were utilized. There were 10483 observations of people who were 40 years of age or older. The American National Sleep Foundation was used to measure self-reported sleep duration. The association between sleep duration and 7-year mortality was assessed using hazard ratios. The longitudinal relationships between short and long sleep duration (using normal or recommended sleep length as a reference) and unfavorable health outcomes were estimated using linear, conditional, and multinomial logistic fixed effects (FE) regressions. RESULTS: This study showed an association between short sleep duration and mortality, hypertension, depressive symptoms, and cardiovascular disease, while there were no significant associations between short sleep duration and diabetes, functional limitations, loneliness, PTSD symptoms, impaired cognition, dynapenia, abdominal obesity, dynapenic abdominal obesity and general obesity. Furthermore, this study found an association between long sleep duration and functional limitations, depressive symptoms, loneliness, PTSD symptoms, impaired or lower cognition, dynapenia, abdominal obesity, dynapenic abdominal obesity and general obesity, while there were no significant associations between long sleep duration and mortality, cardiovascular disease, hypertension, and diabetes. CONCLUSIONS: Short sleep duration was associated with four and long sleep duration with nine adverse health outcomes. The results can be applied to health literacy and education initiatives to promote getting adequate sleep, which is a crucial aspect of total sleep health. Future studies from other countries are recommended.

Sleep medicine 2026 Nov 13 PubMed
22 Mitochondrial respiratory chain activity in the brain of young male rats subjected to alloxan-induced diabetes and a ketamine-induced schizophrenia-like model. Wessler PG et al. 10.1016/j.jpsychires.2026.11.026
View abstract

OBJECTIVE: Type 1 diabetes mellitus (T1D) and schizophrenia (SZ) have both been associated with impaired brain energy metabolism. We investigated whether alloxan-induced insulin-deficient diabetes modifies the effects of a ketamine-induced schizophrenia-like model on the activity of brain mitochondrial respiratory chain enzymes. METHODS: Male Wistar rats (23 days old) were assigned to four groups in a 2 × 2 factorial design: Control, Alloxan, Ketamine, and Ketamine + Alloxan. Diabetes was induced by a single intraperitoneal (i.p.) injection of alloxan (150 mg/kg), and ketamine (25 mg/kg, i.p.) or saline was administered daily from day 4 to day 10. The activities of complexes I, II, II-III and IV were measured in tissue homogenates of the frontal cortex, hippocampus and striatum (n = 4 per group) and analyzed by two-way ANOVA, with correction for multiple testing across all outcomes. No observation was excluded from any analysis. RESULTS: Three effects remained significant after correction for multiple testing: alloxan was associated with lower complex II-III activity in the hippocampus (q = 0.016) and striatum (q = 0.016), and an alloxan × ketamine interaction was observed for complex I in the hippocampus (q = 0.016), where alloxan and ketamine each increased activity compared with controls whereas their combination did not. Before correction, ketamine was also associated with higher complex II activity in the hippocampus (p = 0.006) and interactions were detected for complex II-III (p = 0.046) and complex IV (p = 0.019) in the hippocampus and for complex I in the striatum (p = 0.031); these uncorrected findings should be regarded as exploratory. No significant effect of alloxan, ketamine or their interaction was detected for any enzyme in the frontal cortex. CONCLUSIONS: In this exploratory study, alloxan-induced diabetes and ketamine were associated with region- and enzyme-specific differences in respiratory chain enzyme activity in the hippocampus and striatum, with alloxan attenuating some ketamine-associated increases. These findings require replication in adequately powered studies including both sexes and complementary measures of mitochondrial function.

Journal of psychiatric research 2026 Nov 11 PubMed
23 Synthesis, characterization, in vitro and in silico evaluation of furan-morpholine hybrid Schiff base metal(II) complexes for their potential antidiabetic and antioxidant activities. Nayab S et al. 10.1016/j.bioorg.2026.110733
View abstract

The global burden of type 2 diabetes mellitus necessitates the search for new therapeutic strategies with dual mechanisms of action, addressing both hyperglycemia and associated oxidative stress. Herein, we report a new hybrid furan-morpholine Schiff base ligand, (E)-N-((5-methylfuran-2-yl)methylene)-2-morpholinoethanamine (MFM), as well as its Co(II), Cu(II), Zn(II), and Cd(II) complexes, as potential multitarget agents with antidiabetic and antioxidant capabilities. Single-crystal X-ray diffraction measurements revealed distorted tetrahedral geometries for the Co(II) and Zn(II) complexes, whereas the Cu(II) complex exhibited a dimeric chloro-bridged square-pyramidal structure, and the Cd(II) complex exhibited a distorted square-pyramidal geometry. Among the investigated complexes, [Cu(MFM)Cl] exhibited the highest DPPH radical scavenging activity (IC = 3.01 ± 0.14 μM), significantly exceeding that of the standard ascorbic acid, and the highest inhibition (IC = 5.22 ± 0.33 μM) against α-glucosidase from Saccharomyces cerevisiae, with inhibitory potency comparable to the standard drug acarbose. [Zn(MFM)Cl] showed the strongest inhibition (IC = 4.22 ± 0.25 μM) against α-amylase from porcine pancreas (Sus scrofa), with activity significantly exceeding that of acarbose. The metal complexes' enhanced bioactivity compared with the free ligand underscores the critical role of metal coordination in modulating electronic properties and bioavailability. Exploratory docking yielded scores of -6.96 kcal mol for [Cu(MFM)Cl₂] with α-glucosidase (PDB ID: 3A4A) and - 7.24 kcal mol   for [Zn(MFM)Cl₂] with α-amylase (PDB ID: 1DHK). However, redocking validates only the reference-ligand poses, not the docking protocol for metal complexes. Therefore, docking results are preliminary and hypothesis-generating, providing no definitive evidence of binding affinity or molecular mechanisms. In addition, ADMET predictions showed good pharmacokinetic and drug-likeness features, whereas density functional theory calculations provided insight into the electronic structure, reactivity descriptors, charge distribution, and frontier molecular orbitals of these complexes. In conclusion, the biological activities demonstrated in this study confirm that the furan-morpholine Schiff base scaffolds strongly influence the biological properties of the metal complexes. In particular, the Zn(II) and Cu(II) complexes are promising multifunctional agents for the development of new antidiabetic and antioxidant drugs.

Bioorganic chemistry 2026 Nov 11 PubMed
24 Data-driven cardiometabolic profiling in untreated women with Rotterdam-defined polycystic ovary syndrome: Unsupervised clustering and machine-learning profile assignment. Kurt A et al. 10.1016/j.ejogrb.2026.115546
View abstract

BACKGROUND: Cardiometabolic risk in polycystic ovary syndrome (PCOS) is heterogeneous and may not be fully captured by Rotterdam phenotypes. We aimed to identify data-driven cardiometabolic profiles at initial diagnosis and to evaluate supervised models for profile assignment. METHODS: This retrospective, single-center, clinic-based study included 485 newly diagnosed, untreated women aged 18-45 years with Rotterdam-defined PCOS. Ten routinely available cardiometabolic variables were median-imputed, standardized, reduced by principal component analysis (PCA), and clustered using k-means. Profiles were characterized using variables withheld from clustering and evaluated in missing-data, anthropometry-excluded, age/body mass index-adjusted laboratory-only, and internal assignment-stability analyses. Patient-level cross-validated logistic-regression and random-forest models were used for profile assignment. RESULTS: K-means identified a metabolically favorable profile in 342 patients (70.5%) and a metabolically unfavorable profile in 143 (29.5%). The unfavorable profile showed higher adiposity, central obesity, fasting glucose, triglycerides, low-density lipoprotein cholesterol (LDL-C), total cholesterol, transaminases, white blood cell count, insulin resistance, post-load glucose responses, C-reactive protein (CRP), platelet count, lipid-derived indices, and androgen bioavailability, together with lower sex hormone-binding globulin (SHBG). Rotterdam phenotype distribution did not differ between profiles (P = 0.650). The profile structure was broadly robust to k-nearest-neighbor-imputed and complete-case clustering (adjusted Rand index [ARI] = 0.783 and 0.909, respectively), whereas age/BMI-adjusted laboratory-only clustering showed lower agreement with the primary partition (ARI = 0.307). Training-fold refitting with held-out centroid assignment showed high internal assignment stability (ARI = 0.909). The independent clinical-endocrine model showed moderate discrimination (receiver operating characteristic area under the curve [ROC-AUC], 0.718), whereas secondary cluster-recovery models showed higher discrimination (ROC-AUC, 0.889-0.942; random forest, 0.935). CONCLUSIONS: Routine baseline clinical and laboratory data identified a metabolically unfavorable PCOS profile that was not fully reflected by Rotterdam phenotype distribution in this clinic-based cohort. These exploratory findings require external validation and outcome-based evaluation before their clinical utility can be established.

European journal of obstetrics, gynecology, and reproductive biology 2026 Nov 11 PubMed
25 Adipose NNAT functions as a molecular rheostat to promote or inhibit lipolysis and insulin resistance depending on the dietary context. Wang J et al. 10.1016/j.celrep.2026.118304
View abstract

Insulin and the catecholamines control key metabolic pathways and often act in opposition. Using male mice, we examined the role of the adrenergically regulated ER protein NNAT in adipocytes and found dichotomous effects on systemic insulin sensitivity, dependent on the diet consumed. On a standard diet, inducible, adipocyte-specific deletion of NNAT results in insulin resistance and adipose tissue loss via lipolysis. We identify alterations in Ca handling and activation of ER stress as principal drivers. On a high-fat diet, adipose NNAT deletion ameliorates ER stress and reduces lipolysis by opposing a decline in ER Ca levels. These mice are protected from diet-induced insulin resistance and exhibit increased energy expenditure. NNAT loss also stimulates adiponectin secretion. We conclude that NNAT regulates adipocyte ER stress, systemic insulin signaling, and intertissue communication in a context-dependent manner. For diet-induced obesity and metabolic dysfunction, disrupting the interaction between adipose NNAT and SERCA carries therapeutic potential.

Cell reports 2026 Nov 14 PubMed
26 Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases Fanjing Kong et al. 10.1038/s41467-025-67701-9 35 citations Nature Communications 2026 Scholar
27 Beyond Glycemic Control: Tirzepatide in a Woman With Prior Gestational Diabetes and High Cardiometabolic Risk A. Carducci 10.63620/mkjgomh.2026.1047 Journal of Gynecology Obstetrics and Mother Health 2026 Scholar
28 Sleep patterns, physical activity and glycemic control in newly diagnosed type 2 diabetes patients from a joint perspective: a cross-sectional study Yuanquan Xu et al. 10.3389/fendo.2026.1845188 Frontiers in Endocrinology 2026 Scholar
29 CLINICS OF METABOLIC AND MORPHOMETRIC FACTORS ASSOCIATED WITH THE REMISSION OF TYPE 2 DIABETES AFTER BARIATRIC INTERVENTIONS B. Tavasharov 10.67519/nshr.ztj.2026.03.095 Journal of modern medicine 2026 Scholar
30 Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study Rong Gu et al. 10.2147/DMSO.S592044 Diabetes, Metabolic Syndrome and Obesity 2026 Scholar
31 The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after three years of observation S. Maragkoudakis et al. 10.1093/ejhf/xuag193.1366 European Journal of Heart Failure 2026 Scholar
32 Analysis of Knowledge Level, Self-Efficacy, and Self-Management among Type 2 Diabetes Mellitus Patients in Rural Areas of Aceh Province Rihhadatul Aisy et al. 10.54543/kesans.v5i8.636 KESANS : International Journal of Health and Science 2026 Scholar
33 Exploratory Mediation-Informed Analysis and Dose–Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol T. Jambor et al. 10.3390/medsci14040421 Medical Sciences 2026 Scholar
34 Diagnosis and risk factors in pancreatogenic diabetes. R. K. Sharma et al. 10.1016/bs.acc.2025.10.003 1 citation Advances in clinical chemistry 2026 Scholar
35 Development and validation of a prediction model for cognitive impairment in elderly patients with type 2 diabetes Si-Jie Li et al. 10.3389/fnins.2026.1744871 Frontiers in Neuroscience 2026 Scholar
DoctiPlus Health Insights are compiled weekly from public trial registries, FDA databases, and academic publishers. All figures reflect the seven-day window ending on the report date. Data is provisional and subject to registry updates.

Primary sources

  • ClinicalTrials.gov — public registry
  • openFDA — adverse events & recalls
  • PubMed / NCBI — research papers
  • Semantic Scholar — citations & papers

About this report

  • Category: Diabetes (Type 2)
  • Week: November 9 – November 16, 2026
  • Drugs tracked: New Trials This Week, Recruiting Now, Countries
  • Generated: November 16, 2026 at 11:15 PM
© 2026 DoctiPlus Care Vol. 7 · No. 47 · November 16, 2026 — 30 —